13-May-2024
Arcutis Biotherapeutics Q1 2024 Earnings Preview
Seeking Alpha News (Mon, 13-May 5:35 PM ET)
Notable earnings after Tuesday's close
Seeking Alpha News (Mon, 13-May 5:35 PM ET)
Globe Newswire (Mon, 13-May 8:00 AM ET)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 3-May 4:00 PM ET)
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Globe Newswire (Mon, 29-Apr 4:00 PM ET)
Arcutis Appoints David Topper as Chief Financial Officer
Globe Newswire (Wed, 10-Apr 8:00 AM ET)
Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream
Globe Newswire (Mon, 1-Apr 7:00 AM ET)
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Thu, 28-Mar 8:00 AM ET)
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
Globe Newswire (Mon, 11-Mar 8:00 AM ET)
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Arcutis Biotherapeutics trades on the NASDAQ stock market under the symbol ARQT.
As of May 13, 2024, ARQT stock price climbed to $7.99 with 2,230,256 million shares trading.
ARQT has a beta of 3.02, meaning it tends to be more sensitive to market movements. ARQT has a correlation of 0.11 to the broad based SPY ETF.
ARQT has a market cap of $923.04 million. This is considered a Small Cap stock.
Last quarter Arcutis Biotherapeutics reported $14 million in Revenue and -$.72 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.05.
In the last 3 years, ARQT stock traded as high as $31.62 and as low as $1.76.
The top ETF exchange traded funds that ARQT belongs to (by Net Assets): XBI, VTI, VXF, IWM, IBB.
ARQT has underperformed the market in the last year with a price return of -33.6% while the SPY ETF gained +27.8%. However, in the short term, ARQT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +21.6% vs +4.3% return in SPY. But in the last 2 weeks, ARQT shares have been beat by the market, returning -5.7% compared to an SPY return of +2.5%.
ARQT support price is $7.44 and resistance is $8.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARQT stock will trade within this expected range on the day.